Narrower Q4 Loss for AMAG – Analyst Blog
Zacks Market Commentaries (March 2nd, 2010) Writes:
AMAG Pharmaceuticals Inc. (AMAG) reported a fourth-quarter fiscal 2009 net loss of $18.4 million, or $1.07 per share, which was lower than the year-ago loss of $21.8 million, or $1.28. The Zacks Consensus Estimate for the reported quarter was a loss of $1.08. The lower loss in the quarter was attributable to higher revenues following the approval and subsequent launch of the Feraheme injection. The higher revenue in the quarter more than offset the higher operating costs and expenses in the quarter attributable to increased selling, general and administrative expenses incurred for the commercialization of Feraheme. Revenue for the reported quarter came in at $13.1 million as opposed to $0.6 million in the year-ago period. Net product revenues of Feraheme stood at $12.8 million in the reported quarter, including $1.3 million of $11.5 million in previously deferred product revenues. Total operating costs and expenses for the
...

![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)


